The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksADAM.L Regulatory News (ADAM)

  • There is currently no data for ADAM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Asset Overview: Meize Energy

12 Aug 2020 08:26

RNS Number : 9064V
Adamas Finance Asia Limited
12 August 2020
 

RNS Reach

ADAMAS FINANCE ASIA LIMITED

("ADAM" or the "Company")

 

Asset Overview: Meize Energy Industries Holdings Limited

 

Adamas Finance Asia Limited, the London quoted pan-Asian diversified investment vehicle focused on providing shareholders with attractive uncorrelated, risk adjusted long-term returns, is pleased to make the following announcement regarding its portfolio assets, Meize Energy Industries Holdings Limited ("Meize Energy").

Swift Wealth Investments Limited, a 100% (2018: 100%) owned subsidiary of the Company incorporated in the British Virgin Islands, holds a 7.2% stake in Meize through a redeemable preference share structure.

Meize Energy is one of the largest wind turbine design and wind turbine blade manufacturing companies in China producing internationally certified blades used in wind power generation.

Meize Energy's production facilities are located in Ningxia and Inner Mongolia, primarily producing onshore wind turbine blades. A new production facility has recently been established in Jiangsu. The new production facility is estimated to produce 400 sets of wind turbine blades per annum at full capacity and produces offshore wind turbine blades

Several of the most significant wind energy companies in China deploy Meize Energy wind turbine blades, including Dongfang Electric Corporation, a publicly traded wind energy business. The market is underpinned by inelastic demand, mainly due to Chinese Government support in the form of subsidies, which management believe benefit the long-term prospects of the sector.

For the avoidance of doubt, this RNS contains information already in the public domain, which can be found in the Company's latest annual report and accounts.

For further information, please visit the Company's website at http://adamasfinance.com and follow the Company on Twitter (@AdamasFinance).

FOR FURTHER INFORMATION, PLEASE CONTACT:

 

Adamas Finance Asia Limited

+44 (0) 778 531 5588

John Croft

WH Ireland Limited - Nominated Adviser

+44 (0) 20 7220 1666

James Joyce

James Sinclair Ford

Pello Capital Limited - Joint Corporate Broker

+44 (0) 20 3700 2500

Mark Treharne

Maitland/AMO - Communications Advisor

+44 (0) 20 7379 5151

James Benjamin

Peter Hamid

 

 

 

About Adamas Finance Asia

Adamas Finance Asia Limited (ADAM) is quoted on the AIM Market of the London Stock Exchange and is committed to providing shareholders with attractive uncorrelated, risk adjusted long-term returns from a combination of realising sustainable capital growth and delivering dividend income.

 

The Company is focused on providing growth capital and financing to emerging and established Small and Medium Enterprises (SME) sector throughout Asia, well diversified by national geographies, instruments and asset classes. This vital segment of the economy is underserved by the traditional banking industry for regulatory and structural reasons.

 

The Company's investment manager, Harmony Capital, seeks to capitalise on its team's established investment expertise and broad networks across Asia. Through rigorous diligence and disciplined risk management, Harmony Capital is dedicated to delivering attractive income and capital growth for shareholders with significant downside protection through selectively investing in assets and proactively managing them.

 

Harmony Capital is predominately sourcing private opportunities and continues to create a strong pipeline of attractive income generating assets from potential investments in growth sectors across Asia, including healthcare, fintech, hospitality, IT and property. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAZZGMRNZFGGZG
Date   Source Headline
24th Oct 201810:24 amRNSNet Asset Value Update
16th Oct 201810:34 amRNSDirector/PDMR Shareholding
13th Sep 20187:00 amRNSInterim Results for Six Months Ended 30 June 2018
17th Aug 201811:43 amRNSResult of AGM
13th Aug 201810:50 amRNSNet Asset Value Update
26th Jul 201812:06 pmRNSNet Asset Value Update
23rd Jul 20189:44 amRNSDisposal of Interest in Global Pharm
11th Jul 201810:38 amRNSResult of General Meeting
28th Jun 20183:50 pmRNSPosting of Annual Report and Accounts
21st Jun 20187:00 amRNSAppointment of Broker
21st Jun 20187:00 amRNSFinal Results for the Year Ended 31 December 2017
15th Jun 20188:36 amRNSDisposal of Interest in Global Pharm & GM Notice
27th Apr 20187:00 amRNSUpdate on Disposal of Interest in Global Pharm
26th Apr 20181:57 pmRNSResult of General Meeting
20th Apr 20188:49 amRNSDirector/PDMR Shareholding
5th Apr 20183:54 pmRNSDisposal and Notice of General Meeting
29th Mar 20187:00 amRNSUpdate on Disposal of Interest in Global Pharm
26th Mar 20184:44 pmRNSIncreased Ownership in HKMH
19th Mar 20187:00 amRNSNew Investment
8th Feb 201812:17 pmRNSUpdate - Net Asset Value
2nd Feb 20188:24 amRNSDirector/PDMR Shareholding
15th Jan 20187:00 amRNSFurther re. Disposal of Interest in Global Pharm
21st Dec 20178:54 amRNSIncrease in Shareholding in Hong Kong Mining
31st Oct 201710:23 amRNSNet Asset Value Update
2nd Oct 20177:00 amRNSAppointment of Director
22nd Sep 20177:00 amRNSInterim Results For Six Months End 30 June 2017
20th Sep 201711:18 amRNSAGM and Share Consolidation
15th Sep 20177:00 amRNSDisposal of Interest in Global Pharm
30th Aug 20174:50 pmRNSProposed Share Consolidation
4th Aug 20173:36 pmRNSUpdate on Global Pharm Convertible Bond
27th Jul 20177:00 amRNSNet Asset Value(s)
20th Jul 20179:43 amRNSDirectorate Change
20th Jul 20179:27 amRNSAnnual General Meeting
3rd Jul 20179:14 amRNSAppointment of Director
29th Jun 201710:45 amRNSFinal Results
22nd Jun 20178:46 amRNSFurther Payment of Proceeds for TTS Disposal
15th Jun 20179:43 amRNSPayment of Proceeds for TTS Project Disposal
25th May 201711:06 amRNSResult of Meeting
2nd May 20177:00 amRNSChange of Investment Manager and Investing Policy
24th Feb 201711:45 amRNSUPDATE ON TTS PROJECT DISPOSAL
8th Feb 20179:26 amRNSUPDATE ON TTS PROJECT DISPOSAL
31st Jan 20177:00 amRNSDistribution from GCCF
23rd Jan 20179:15 amRNSUPDATE: REDEMPTION OF GLOBAL PHARM CONVERTIBLE
13th Jan 20178:15 amRNSUPDATE ON TTS PROJECT DISPOSAL
4th Jan 20179:00 amRNSProposed Disposal
29th Dec 20167:00 amRNSDirector/PDMR Shareholding
22nd Dec 20161:18 pmRNSDirector/PDMR Shareholding
20th Dec 20164:19 pmRNSDirector/PDMR Shareholding
13th Dec 20169:23 amRNSDirector/PDMR Shareholding
6th Dec 201612:34 pmRNSCorrection to Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.